drugset
drugset / Trial / NCT01757145

Eltrombopag for Enhancing Platelet Engraftment in Adult Patients Undergoing Cord Blood Transplantation

NCT01757145 ↗

Phase 2 Unknown 20 enrolled Rabin Medical Center
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether Eltrombopag may shorten time to platelet engraftment after allogeneic cord blood transplantation.

Timeline

Start
2013-01
Primary completion
2016-06
Completion
2016-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Eltrombopag Small molecule 300 mg Oral

Indications

bone marrow failure syndrome hematopoietic and lymphoid cell neoplasm